Quarterly report pursuant to Section 13 or 15(d)

Financial Information Relating to Reportable Segments (Detail)

v2.4.0.8
Financial Information Relating to Reportable Segments (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Segment Reporting Information [Line Items]    
Net sales $ 108,477 $ 85,668
Cost recognized on sale of acquired inventory (3,167) (1,731)
Amortization of acquisition related intangible assets (5,728) (2,188)
Selling, general and administrative expenses (28,701) (14,021)
Acquisition- related expenses (2,370) (532)
Consolidated operating income 35,216 39,391
Reportable Segment
   
Segment Reporting Information [Line Items]    
Consolidated operating income 49,159 45,007
Reportable Segment | Biotechnology
   
Segment Reporting Information [Line Items]    
Net sales 81,468 73,190
Consolidated operating income 42,020 40,988
Reportable Segment | Clinical Controls
   
Segment Reporting Information [Line Items]    
Net sales 14,095 12,478
Consolidated operating income 4,535 4,019
Reportable Segment | Protein Platforms
   
Segment Reporting Information [Line Items]    
Net sales 12,914 0
Consolidated operating income 2,604 0
Corporate, Non-Segment
   
Segment Reporting Information [Line Items]    
Selling, general and administrative expenses $ (2,678) $ (1,165)